RCKT
Rocket·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Consensus Rating "Strong Buy"
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RCKT
Rocket Pharmaceuticals, Inc.
A leading late-stage, clinical biotech company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders
Biological Technology
07/07/1999
02/18/2015
NASDAQ Stock Exchange
299
12-31
Common stock
9 Cedarbrook Drive, Cranbury, NJ 08512
--
Rocket Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on July 7, 1999. The company is a fully integrated, late-stage biotechnology company focused on developing first-of-its-kind, unique and best-in-class gene therapies with direct targeted mechanisms of action and clear clinical endpoints for rare and destructive diseases.
Company Financials
EPS
RCKT has released its 2025 Q3 earnings. EPS was reported at -0.45, versus the expected -0.52, beating expectations. The chart below visualizes how RCKT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
